John Revill

Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor: Discovery of 2-[(3<i>S</i>)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017)

James S. Scott, Suzanne S. Bowker, Joanne deSchoolmeester et al. · Journal of Medicinal Chemistry · 2012 · 62 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes

William McCoull, Matthew S. Addie, Alan M. Birch et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 44 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

An efficient synthesis of the γ-lactone corresponding to a hydroxyethylene dipeptide isostere using stereoselective bromolactonisation of a chiral acyloxazolidinone

Robert H. Bradbury, John Revill, Janet E. Rivett et al. · Tetrahedron Letters · 1989 · 28 citations

Natural Sciences, Chemistry, Organic Chemistry +2

Merrifield, Alpha-MethoxyPhenyl (MAMP) resin; a new versatile solid support for the synthesis of secondary amides

Dearg S. Brown, John Revill, Richard E. Shute · Tetrahedron Letters · 1998 · 14 citations

Natural Sciences, Chemistry, Medicinal Chemistry +5

Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

James S. Scott, Adrian L. Gill, Linda Godfrey et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 12 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15